Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker BLCO
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Frederick Munsch SVP, Controller and CAO | BLCO Bausch + Lomb Corporation | Sale | 112,015 | $20.48 | $2.3M Sale | Form 4 ↗ |
| Aug 10, 2026 | Frederick Munsch SVP, Controller and CAO | BLCO Bausch + Lomb Corporation | Sale | 52,900 | $16.78 | $887.7K Sale | Form 4 ↗ |
| Aug 7, 2026 | Andrew C. Von Eschenbach Director | BLCO Bausch + Lomb Corporation | Sale | 6,059 | $16.58 | $100.5K Sale | Form 4 ↗ |
| Aug 6, 2026 | Andrew C. Von Eschenbach Director | BLCO Bausch + Lomb Corporation | Sale | 12,500 | $16.50 | $206.3K Sale | Form 4 ↗ |
| Mar 6, 2026 | A. Robert D. Bailey EVP & Chief Legal Officer | BLCO Bausch + Lomb Corporation | Buy | 14,600 | $17.15 | $250.4K Buy | Form 4 ↗ |
| Mar 6, 2026 | Sam Eldessouky EVP and CFO | BLCO Bausch + Lomb Corporation | Buy | 4,000 | $17.13 | $68.5K Buy | Form 4 ↗ |
| Mar 6, 2026 | Brent L. Saunders CEO and Chairman of the Board, Director | BLCO Bausch + Lomb Corporation | Buy | 14,700 | $17.14 | $252.0K Buy | Form 4 ↗ |
| Mar 3, 2026 | Thomas W. Ross Sr. Director | BLCO Bausch + Lomb Corporation | Buy | 4,500 | $17.68 | $79.6K Buy | Form 4 ↗ |
| Mar 2, 2026 | Eduardo Alfonso Director | BLCO Bausch + Lomb Corporation | Buy | 4,300 | $17.90 | $77.0K Buy | Form 4 ↗ |
| Feb 27, 2026 | Andrew C. Von Eschenbach Director | BLCO Bausch + Lomb Corporation | Buy | 4,364 | $18.31 | $79.9K Buy | Form 4 ↗ |
| Feb 23, 2026 | Steven H. Collis Director | BLCO Bausch + Lomb Corporation | Buy | 15,000 | $17.81 | $267.1K Buy | Form 4 ↗ |
| Feb 20, 2026 | Russel C. Robertson Director | BLCO Bausch + Lomb Corporation | Buy | 4,400 | $17.90 | $78.8K Buy | Form 4 ↗ |
| Feb 19, 2026 | Karen Ling Director | BLCO Bausch + Lomb Corporation | Buy | 4,000 | $17.74 | $71.0K Buy | Form 4 ↗ |
| May 22, 2025 | Brent L. Saunders CEO and Chairman of the Board, Director | BLCO Bausch + Lomb Corporation | Buy | 22,000 | $11.28 | $248.2K Buy | Form 4 ↗ |
| May 2, 2025 | Andrew C. Von Eschenbach Director | BLCO Bausch + Lomb Corporation | Buy | 1,695 | $11.76 | $19.9K Buy | Form 4 ↗ |
15 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances